AUTHORS
Qian Sun, MD, Hongrui Zhang, MD2, Ping Ma3, Wenjie Liu, MD4, Yu Zhu, MD5, Sixuan Qian6, Jianyong Li, MD7, Lei Fan, MD8, Ming Hong, MD9
AFFILIATIONS
1 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
2 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
3 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
4 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
5 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
6 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
7 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
8 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
9 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
ABSTRACT
Objective: To investigate the efficacy and safety of idarubicin plus cytarabine (IA) combined with hypomethylating agents (HMA, decitabine/azacitidine) versus standard IA as induction therapy for newly diagnosed young adult acute myeloid leukemia (AML), aiming to improve remission quality and long-term survival.
Methods: This prospective, multicenter, randomized controlled trial (ChiCTR2000036086) enrolled 106 newly diagnosed AML (non-APL) patients aged 18-59 years from three centers between October 2020 and August 2022. Patients were randomly assigned 1:1 to receive HMA-IA (n=53) or IA (n=53). HMA-IA: decitabine (20 mg/m2/d, days 1-5) or azacitidine (75 mg/m2/d, days 1-7) plus idarubicin (10 mg/m2/d, days 1-3) and cytarabine (100 mg/m2/d, days 1-7). IA: idarubicin (10-12 mg/m2/d, days 1-3) plus cytarabine (same). After 1-2 induction cycles, patients achieving CR received consolidation with intermediate-to-high-dose cytarabine; eligible patients underwent Hematopoietic Stem Cell Transplantation (HSCT). Primary endpoints: overall response rate (ORR) and composite complete remission CRc (CR+CRi) rate. Secondary endpoints: measurable residual disease (MRD) negativity (<0.1% by flow cytometry) in CR, overall survival (OS), disease-free survival (DFS), hematopoietic recovery, and adverse events (AEs).
Results: Baseline characteristics were balanced except for more females and IDH1 mutations in HMA-IA, and more CEBPA bZIP mutations in IA. After cycle 1, ORR was 88.7% (HMA-IA) vs 79.2% (IA) (P=0.186); CRc: 71.7% vs 75.5% (P=0.659). Among CR patients, MRD negativity was significantly higher in HMA-IA (73.7% vs 50.0%, P=0.032). At median follow-up 24 months, 1-/2-year OS: 83.0%/62.3% (HMA-IA) vs 82.5%/65.5% (IA) (P=0.670). Median DFS: 16.1 vs 22.6 months; 2-year DFS: 49.4% vs 39.9% (P=0.319). Subgroup analysis: HMA-IA prolonged DFS in females (P=0.043) but not males. Neutrophil and platelet recovery times were similar (~19-22 days). Grade ≥3 hematologic AEs: 100% both groups. Non-hematologic: hypotension and edema (grade ≤2) more frequent in HMA-IA (P<0.05); hyperbilirubinemia higher in IA (P=0.031). No other significant differences.
Conclusions: Adding HMA to IA did not improve early remission rates but significantly increased MRD negativity in CR patients, indicating deeper remission through epigenetic modulation. The regimen did not increase severe myelosuppression, with manageable toxicities. The HMA-IA regimen is safe and effective; its MRD advantage may confer long-term survival benefits, providing a new induction option for young AML adults.
DISCLOSURES
Wenjie Liu, MD: No relevant conflicts of interest to declare.